NeuroOne Medical Technologies Corporation Announces Restatement of Q2 2026 Financial Results
NeuroOne Medical Technologies Corporation (“NeuroOne”, Nasdaq: NMTC), a company specializing in medical technology innovations, has issued an Amendment No. 1 to its Quarterly Report on Form 10-Q/A for the quarter ended March 31, 2026. This amended filing contains restated financial statements and disclosures following the identification and correction of certain misstatements in the previously reported results. The restatement, revised risk factors, and other key items are potentially price-sensitive and warrant close attention from investors and shareholders.
Key Points from the Restated Report
- Restatement of Financial Statements: The Company has restated its unaudited condensed financial statements for the quarter and six months ended March 31, 2026, including the balance sheet, statements of operations, stockholders’ equity, and cash flows. All relevant notes to the financial statements have also been updated.
-
Scope of Amendments: The restatement affects:
- Part I, Item 1: Financial Statements (including all core financial statements and related notes)
- Part I, Item 2: Management’s Discussion and Analysis of Financial Condition and Results of Operations
- Part I, Item 4: Controls and Procedures
- Part II, Item 1A: Risk Factors
- New CEO and CFO certifications as of the date of the Amended Report
No other items from the original filing have been amended, and the Amended Report does not reflect events after the date of the original filing unless related to the restatement.
- Reverse Stock Split: On April 14, 2026, NeuroOne executed a reverse stock split of its issued and outstanding common shares at a ratio of 1-for-X (the exact ratio is not specified in the excerpt), with trading beginning on a split-adjusted basis. Shareholders entitled to fractional shares received a cash payment equivalent to the market value of the fractional share. The split was uniform for all shareholders and did not alter their proportional ownership, except for adjustments related to fractional shares.
- Restatement Details: The restatement was triggered by the identification of misstatements. In accordance with ASC 250, “Accounting Changes and Error Corrections,” the company has revised previously issued financial statements, impacting the balance sheet, statement of operations, equity, and cash flows. The impacted financials include corrections to line items such as accounts receivable, retained earnings/accumulated deficit, total stockholders’ equity, and net loss per share.
- Impact on Shareholders’ Equity: As of March 31, 2026 (as restated), the total stockholders’ equity was reported as \$5,077,283, following an adjustment from the previously reported \$5,373,636. The accumulated deficit increased to \$(82,429,699) from the previously reported \$(82,133,346).
- Net Loss per Share: The restated net loss per share (basic and diluted) for the six months ended March 31, 2026, is \$(0.45) and \$(0.47), respectively, compared to the previously reported \$(0.42) and \$(0.44). For the three months ended March 31, 2026, the restated loss per share is \$(0.28) (basic and diluted), as opposed to \$(0.26) previously.
- Shares Outstanding: As of June 10, 2026, the company had 8,701,526 shares of common stock outstanding.
- Company Classification: NeuroOne is classified as a non-accelerated filer and a smaller reporting company. It is not a shell company.
- Restatement Tables: The company provides detailed tables comparing previously reported, adjustment, and restated values for key balance sheet, income statement, and cash flow items. Investors should review these for a full understanding of the magnitude and nature of the corrections.
- Supplemental Note: The restatement does not reflect any changes or events occurring after the original filing date, except as necessary to correct the identified misstatements.
Additional Items of Potential Impact to Shareholders
- Potential Price Sensitivity: Restatements of financial statements can have significant impacts on share price, especially when they involve corrections to net income/loss, earnings per share, and stockholders’ equity. The increased net loss and lower equity position may affect investor sentiment and analyst ratings.
- Controls and Procedures: The company has amended its disclosures regarding controls and procedures, which may indicate remedial actions or changes in internal control over financial reporting. Investors should monitor for further updates or disclosures regarding the root cause of the misstatements and any ongoing controls remediation.
- Risk Factors: As part of the amendment, the company has updated risk factors. While the excerpt does not specify the newly added risks, updates to this section can be material and influence risk assessments.
- CEO/CFO Certifications: New certifications by executive management are included, affirming the accuracy of the amended filings as of the date of the amendment.
Summary for Investors
The restatement of NeuroOne’s Q2 2026 financial statements, including increased net losses and a decrease in shareholders’ equity, is a material event that investors should carefully consider. Such restatements can signal issues in financial controls or prior reporting accuracy, and may impact share valuations in the near term. The reverse stock split and subsequent changes in share count and per-share metrics are also relevant for valuation and trading considerations. Investors should review the amended report in detail and monitor for further disclosures from the company regarding the causes of the restatement and any additional impacts.
Disclaimer: This article is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell any securities. Investors should conduct their own due diligence and consult with financial advisors before making investment decisions. The information provided is based on publicly available filings and may be subject to further updates or corrections.
